Medtronic (MDT) Receives FDA Clearance Of MiniMed Connect For More Convenient Access To Personal Diabetes Data

Friday, June 5, 2015

Source: Device Space

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed® Connect. Designed to provide a mobile connection to critical information for managing diabetes, MiniMed Connect is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone and provides remote monitoring and text message notifications for their loved ones. It also gives healthcare teams more convenient access to more comprehensive patient data so they can adjust their patients' care plans. The new product clearance was announced from the American Diabetes Association 75th Scientific Sessions in Boston and will be on display at Booth #437.

MiniMed Connect consists of a small device that easily fits on a keychain or in a pocket, a smartphone app for the person with diabetes, and a web display on desktop or mobile devices for their care partners. The MiniMed Connect device securely transmits pump and sensor glucose data from the patient's MiniMed insulin pump to the app and web display, which shows real-time sensor glucose and insulin information on the phone or any Internet-enabled device anytime, anywhere. The system also delivers preset text notifications to loved ones when the person with diabetes' glucose values go too high or too low, or when an alarm on the pump isn't cleared, providing greater peace of mind for care partners. In addition, MiniMed Connect provides healthcare teams with more comprehensive data, and with more convenient access to their patients' diabetes data so they can adjust care plans.

View All News »